UPDATE: PerkinElmer Revenues Climb 14 Percent in Second Quarter | GenomeWeb

The article has been updated to provide additional information.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that revenues for the second quarter climbed nearly 14 percent, outpacing consensus analyst estimates.

In the three months ended July 4, the company posted revenues of $497.8 million, up from $438.3 million a year ago. Wall Street had expected revenues of $464.7 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.